Jacobs Levy Equity Management
CUE icon

Jacobs Levy Equity Management’s Cue Biopharma CUE Stock Holding History

Jacobs Levy Equity Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,317
Closed -$198K – 982
2022
Q4 		$198K Buy
+2,317
New +$212K ﹤0.01% 910

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management's CUE Position: Q1 2023 in Review

Jacobs Levy Equity Management sold out of Cue Biopharma (CUE) in Q1 2023, closing a stake of 2,317 shares — an estimated $198K sold.

Jacobs Levy Equity Management first reported a position in CUE in Q4 2022 and held it in 1 quarter. The position peaked at $198K in Q4 2022. 63 funds tracked by Wall St. Rank hold CUE as of Q1 2023.

  • Jacobs Levy Equity Management reported no remaining Cue Biopharma position as of Q1 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,317 Cue Biopharma shares in Q1 2023, an estimated $198K.
  • Jacobs Levy Equity Management first reported a position in Cue Biopharma in Q4 2022 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Cue Biopharma position peaked at $198K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2023, filed 15 May 2023.